Docbot, an artificial intelligence (AI) technology company focusing on gastrointestinal (GI) disease, has raised a $4M Series A led by Khosla Ventures, with participation by Bold Capital Partners, Collaborative Fund and Boutique Venture Partners, bringing the total amount raised to $8.5M.

Docbot's products are built on the UltivisionAI software platform for real-time image analysis, automated reporting, and analytic tools to improve patient care and clinical workflows. UltivisionAI is an investigational device and has not received FDA clearance.